microRNA-132 regulates gene expression programs involved in microglial homeostasis

Hannah Walgrave1,2, Amber Penning3, Giorgia Tosoni3

  • 1VIB-KU Leuven Center for Brain & Disease Research, 3000 Leuven, Belgium.

Iscience
|May 30, 2023
PubMed

Insights

microRNA-132 (miR-132) is downregulated in Alzheimer's disease (AD). Restoring miR-132 shifts microglia to a healthy state, offering a potential therapeutic avenue for AD.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • microRNA-132 (miR-132) is significantly downregulated in Alzheimer's disease (AD) brains.
  • Increasing miR-132 in AD mouse models improves pathologies and cognitive function.
  • Further investigation is needed to understand miR-132's pleiotropic effects for therapeutic development.

Purpose of the Study:

  • To identify molecular pathways targeted by miR-132 in the mouse hippocampus.
  • To analyze the effects of miR-132 modulation on microglial cell states.

Main Methods:

  • Utilized miR-132 loss- and gain-of-function approaches.
  • Employed single-cell transcriptomics, proteomics, and in silico AGO-CLIP datasets.
  • Confirmed findings using human induced pluripotent stem cell-derived microglia.

Main Results:

  • miR-132 modulation significantly impacts the transition of microglia from a disease-associated to a homeostatic state.
  • Identified specific molecular pathways regulated by miR-132 in the hippocampus.
  • Demonstrated miR-132's regulatory role in microglial state shifts in human cell cultures.

Conclusions:

  • miR-132 plays a crucial role in regulating microglial states, shifting them towards homeostasis.
  • These findings highlight miR-132 as a potential therapeutic target for Alzheimer's disease.
  • Understanding miR-132's molecular targets is key for developing effective AD treatments.